Company intelligence / Profile preview
Expression Therapeutics
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
Expression Therapeutics has developed advanced gene and cell therapies targeting bleeding disorders like hemophilia A/B and several cancers. Their proprietary technologies include optimized lentiviral/AAV vector systems for gene delivery and a unique CAR-T platform using gamma delta T cells. The company operates a large cGMP manufacturing facility to support its pipeline. No recent clinical trial results are publicly available as of this search.
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Gene therapy (lentiviral vectors, adeno-associated viral vectors)Allogeneic cell therapy (gamma delta T cells with proprietary CAR technology)Recombinant proteins
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Expression Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Expression Therapeutics.